Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program for lead asset IMM-1-104 following favorable data against pancreatic cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback